IL-17C/IL-17受体E信号在CD4+ T细胞中促进TH17细胞驱动的肾小球炎症
该研究发现急性ANCA相关性新月体肾炎患者血清IL-17C水平显著升高,而IL-17A、F、E未见升高。在小鼠新月体肾炎和狼疮肾炎模型中,IL-17C或IL-17RE缺陷可减轻肾损伤并减少TH17反应,IL-17RE在CD4+ TH17细胞高表达,提示IL-17C/IL-17RE通路是潜在治疗靶点。
要点
- 急性ANCA相关性新月体肾炎患者血清IL-17C显著升高。
- IL-17C或IL-17RE缺陷减轻小鼠新月体肾炎和狼疮肾炎。
- IL-17C通过CD4+ TH17细胞上的IL-17RE促进TH17反应。
核心结论
- IL-17C通过CD4+ TH17细胞表达的IL-17RE促进TH17细胞反应和免疫介导的肾脏疾病。
- 靶向IL-17C/IL-17RE通路可能为TH17诱导的自身免疫性疾病提供治疗策略。
研究设计与样本
- 比较急性ANCA相关性新月体肾炎患者与健康对照的血清IL-17家族细胞因子水平。
- 使用新月体肾炎(肾毒血清肾炎)和降植烷诱导狼疮肾炎小鼠模型,评估IL-17C或IL-17RE缺陷的影响。
- 进行骨髓移植实验确定IL-17C来源,并分析CD4+ TH17细胞IL-17RE表达。
主要发现
- 急性ANCA相关性新月体肾炎患者血清IL-17C水平较健康对照显著升高,而IL-17A、F、E未升高。
- IL-17C缺陷显著改善新月体肾炎小鼠的肾组织损伤和肾功能。
- IL-17RE缺陷对新月体肾炎提供类似保护作用,且保护效应与TH17反应降低相关。
- 骨髓移植实验显示IL-17C由组织驻留细胞而非淋巴细胞产生。
- IL-17RE在CD4+ TH17细胞高表达,其缺失阻止TH17反应和后续组织损伤。
临床怎么用
- IL-17C/IL-17RE通路可作为TH17驱动自身免疫性肾小球疾病的潜在治疗靶点。
- 急性ANCA相关性新月体肾炎患者血清IL-17C升高提示其可能作为疾病相关生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The IL-17 cytokine family and the cognate receptors thereof have a unique role in organ-specific autoimmunity. Most studies have focused on the founding member of the IL-17 family, IL-17A, as the central mediator of diseases. Indeed, although pathogenic functions have been ascribed to IL-17A and IL-17F in the context of immune-mediated glomerular diseases, the specific functions of the other IL-17 family members in immunity and inflammatory kidney diseases is largely unknown. Here, we report that compared with healthy controls, patients with acute Anti-neutrophil cytoplasmatic antibody (ANCA)-associated crescentic glomerulonephritis (GN) had significantly elevated serum levels of IL-17C (but not IL-17A, F, or E). In mouse models of crescentic GN (nephrotoxic nephritis) and pristane-induced lupus nephritis, deficiency in IL-17C significantly ameliorated the course of GN in terms of renal tissue injury and kidney function. Deficiency of the unique IL-17C receptor IL-17 receptor E (IL-17RE) provided similar protection against crescentic GN. These protective effects associated with a reduced TH17 response. Bone marrow transplantation experiments revealed that IL-17C is produced by tissue-resident cells, but not by lymphocytes. Finally, IL-17RE was highly expressed by CD4+ TH17 cells, and loss of this expression prevented the TH17 responses and subsequent tissue injury in crescentic GN. Our findings indicate that IL-17C promotes TH17 cell responses and immune-mediated kidney disease via IL-17RE expressed on CD4+ TH17 cells. Targeting the IL-17C/IL-17RE pathway may present an intriguing therapeutic strategy for TH17-induced autoimmune disorders.
引用
- Krohn S, Nies JF, Kapffer S, et al. IL-17C/IL-17 Receptor E Signaling in CD4+ T Cells Promotes TH17 Cell-Driven Glomerular Inflammation. J Am Soc Nephrol. 2018. PMID: 29483158. doi:10.1681/ASN.2017090949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。